← Back to Search

Platelet Lysate

CAM-101 30% for Dry Eye Syndrome

Phase 1 & 2
Waitlist Available
Research Sponsored by Cambium Medical Technologies LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 42 days
Awards & highlights

Summary

The purpose of this Phase 1/2 study is to compare the safety and tolerability of four times a day (QID) dosing of a non-preserved topical ocular drop formulation of 10 vol/vol % and 30 vol/vol % of FD hPL to vehicle control eye drops in patients with Dry Eye Disease (DED) secondary to Graft vs. Host Disease (GvHD).

Eligible Conditions
  • Dry Eye Syndrome
  • Eye Discomfort
  • Graft-versus-Host Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~42 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 42 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with ocular treatment-related adverse events as assessed by CTCAE v4.0
Number of participants with systemic treatment-related adverse events as assessed by CTCAE v4.0
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Secondary outcome measures
Efficacy as measured by change in corneal staining
Efficacy as measured by ocular discomfort using the 100 point visual analogue scale (VAS) scores
Efficacy as measured by ocular surface disease index (OSDI)

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: CAM-101 30%Experimental Treatment1 Intervention
FD hPL 30 vol/vol %
Group II: CAM-101 10%Experimental Treatment1 Intervention
FD hPL 10 vol/vol %
Group III: Vehicle ControlPlacebo Group1 Intervention
PlasmaLyte-A, vehicle control, a preservative-free ophthalmic drop
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CAM-101 10%
2018
Completed Phase 2
~70
CAM-101 30%
2018
Completed Phase 2
~70

Find a Location

Who is running the clinical trial?

Cambium Medical Technologies LLCLead Sponsor
Oregon Health and Science UniversityOTHER
994 Previous Clinical Trials
7,386,884 Total Patients Enrolled
University of MichiganOTHER
1,833 Previous Clinical Trials
6,423,064 Total Patients Enrolled
~9 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top